AI Article Synopsis

  • The 1970s discovery by Hepler and Frank indicated that marijuana can lower intraocular pressure, sparking interest in cannabinoids as potential treatments.
  • Despite extensive research, no drugs that modulate the endocannabinoid system (ECS) have been approved for eye-related conditions yet.
  • Advances in understanding the ECS and new pharmacological tools are reviving interest in developing ECS-based therapies for glaucoma and other ocular diseases.

Article Abstract

The observation that marijuana reduces intraocular pressure was made by Hepler and Frank in the 1970s. Since then, there has been a significant body of work investigating cannabinoids for their potential use as therapeutics. To date, no endocannabinoid system (ECS)-modulating drug has been approved for clinical use in the eye; however, recent advances in our understanding of the ECS, as well as new pharmacological tools, has renewed interest in the development of ocular ECS-based therapeutics. This review summarizes the current state-of-affairs for the use of ECS-modulating drugs for the treatment of glaucoma and ocular inflammatory and ischemic disease.

Download full-text PDF

Source
http://dx.doi.org/10.1515/jbcpp-2015-0065DOI Listing

Publication Analysis

Top Keywords

endocannabinoid system
8
horizon targeting
4
targeting endocannabinoid
4
system treatment
4
treatment ocular
4
ocular disease
4
disease observation
4
observation marijuana
4
marijuana reduces
4
reduces intraocular
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!